Notably, the antibodies effectively targeted leukemic stem cells in bone marrow samples and mouse models, which Flynn noted as “critical” because a handful of leukemia stem cells can ...

AML originates from a rare population of cells, termed leukemic stem cells (LSCs) or leukemia-initiating cells, which are capable of self-renewal, proliferation and differentiation into malignant ...

Targeting ferritinophagy impairs quiescent cancer stem cells in acute myeloid leukemia in vitro and in vivo models. Science Translational Medicine , 2024; 16 (757) DOI: 10.1126/scitranslmed ...

Researchers have discovered 2 leukemia stem cell subtypes with distinct epigenetic and transcriptional signatures. “Our study sets the stage to unlock new insights into the mechanisms governing ...

Acute myelogenous leukemia, or AML, remains one of the most aggressive blood cancers. Each year, around 44,000 people in the ...

All the patients in the phase 2 study received cyclophosphamide, tacrolimus and mycophenolate mofetil for graft-vs-host ...

Congratulations to Emeline Boet (PhD Tamburini's group), winner of the poster session held at the CRTOH retreat on May 26-27, 2025 in the Post Doc Category.

First patient dosed with Debiopharm's first-in-class CD37 targeted antibody drug conjugate (ADC) in a Phase 1/2, multicenter, open-label trial, for patients with acute myeloid leukemia (AML) Debiophar ...